China Interest Debt Per Share from 2010 to 2024
CPHI Stock | USD 0.32 0.02 6.67% |
Interest Debt Per Share | First Reported 2010-12-31 | Previous Quarter 1.45636196 | Current Value 1.38 | Quarterly Volatility 5.35288778 |
Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 349.9 K or Selling General Administrative of 1.4 M, as well as many exotic indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0019 or PTB Ratio of 0.26. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
China | Interest Debt Per Share |
Latest China Pharma's Interest Debt Per Share Growth Pattern
Below is the plot of the Interest Debt Per Share of China Pharma Holdings over the last few years. It is China Pharma's Interest Debt Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in China Pharma's overall financial position and show how it may be relating to other accounts over time.
Interest Debt Per Share | 10 Years Trend |
|
Interest Debt Per Share |
Timeline |
China Interest Debt Per Share Regression Statistics
Arithmetic Mean | 5.23 | |
Geometric Mean | 3.43 | |
Coefficient Of Variation | 102.27 | |
Mean Deviation | 3.96 | |
Median | 3.65 | |
Standard Deviation | 5.35 | |
Sample Variance | 28.65 | |
Range | 18.4407 | |
R-Value | (0.09) | |
Mean Square Error | 30.61 | |
R-Squared | 0.01 | |
Significance | 0.75 | |
Slope | (0.11) | |
Total Sum of Squares | 401.15 |
China Interest Debt Per Share History
About China Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include China Pharma income statement, its balance sheet, and the statement of cash flows. China Pharma investors use historical funamental indicators, such as China Pharma's Interest Debt Per Share, to determine how well the company is positioned to perform in the future. Although China Pharma investors may use each financial statement separately, they are all related. The changes in China Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on China Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on China Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in China Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Interest Debt Per Share | 1.46 | 1.38 |
Pair Trading with China Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with China Stock
0.87 | IRNRF | Iron Road Limited | PairCorr |
Moving against China Stock
0.77 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
0.76 | BAC | Bank of America Financial Report 16th of July 2024 | PairCorr |
0.75 | XOM | Exxon Mobil Corp Sell-off Trend | PairCorr |
0.74 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
0.7 | DD | Dupont De Nemours Sell-off Trend | PairCorr |
The ability to find closely correlated positions to China Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Pharma Holdings to buy it.
The correlation of China Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Pharma Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of China Pharma Correlation against competitors. Note that the China Pharma Holdings information on this page should be used as a complementary analysis to other China Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is China Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 2.072 | Quarterly Revenue Growth (0.26) | Return On Assets (0.10) | Return On Equity (0.52) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.